Omica's Advanced In Vitro Toxicology Solutions: Leading the Future of Ethical and Regulatory-Compliant Product Safety Testing

We provide comprehensive, high-throughput testing platforms designed for medical devices, pharmaceuticals, and cosmetic products. Our expertise lies in developing and validating advanced in vitro models that replicate human biological systems, enabling precise toxicity profiling and safety assessments in compliance with global regulatory standards.

Key areas of our in vitro toxicology services include:

1. Skin and Eye Irritation Testing: Utilizing OECD-compliant platforms such as the KeratinoSens for skin sensitization and OECD 492 for eye irritation, Omica delivers robust, reproducible data for assessing irritation and sensitization potential, particularly for medical devices and consumer products. Our focus on alternative test models ensures compliance with ISO 10993 biocompatibility standards.

2. Cytotoxicity and Genotoxicity Testing: Our in vitro cytotoxicity assays evaluate the potential harmful effects of compounds or medical devices on living cells. At the same time, our genotoxicity assessments detect DNA damage, ensuring the safety of products during early development phases.

3. High-Throughput Screening (HTS) and Mechanistic Toxicology: Leveraging state-of-the-art HTS technology, Omica provides rapid, large-scale screening of compounds for toxicity endpoints such as hepatotoxicity, neurotoxicity, and cardiotoxicity. These assays offer mechanistic insights into compound behavior, facilitating early-stage risk assessments.

4. 3D Tissue Models and Organ-on-a-Chip: Omica is pioneering the use of 3D human tissue models and organ-on-a-chip technologies, which simulate complex tissue architecture and organ-level functions, providing more physiologically relevant data than traditional 2D models.

5. Endocrine Disruption and Reproductive Toxicity: Our in vitro models assess the effects of compounds on endocrine signaling pathways, reproductive health, and hormone regulation, offering crucial data to meet regulatory requirements for endocrine disruptor screening programs.

6. Biocompatibility Testing for Medical Devices: Focusing on the ISO 10993 series, we offer a full suite of tests, including cytotoxicity, sensitization, irritation, and endotoxin assays, to ensure that medical devices are safe for human use without relying on animal models.

Omica’s in vitro toxicology platform delivers precise, human-relevant data and aligns with global efforts to reduce animal testing, offering a sustainable and scientifically superior approach to product safety testing. Our capabilities are trusted by industries looking for innovative, compliant, and reliable solutions for early-stage safety assessments and regulatory approval.